Tyrosine phosphorylation in human lymphomas

Histochemical Journal

Volumn 34, Issue 11-12, 2002, Pages 545-552

  Haralambieva, E ^a   Jones, M ^a   Roncador, G M ^a   Cerroni, L ^b   Lamant, L ^c   Ott, G ^d   Rosenwald, A ^d   Sherman, C ^e   Thorner, P ^e   Kusec, R ^f   Wood, K M ^g   Campo, E ^h   Falini, B ⁱ   Ramsay, A ^j   Marafioti, T ^a   Stein, H ^k   Kluin, P M ^l   Pulford, K ^a   Mason, D Y ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GRAZ   (Austria)

^c CHU PURPAN   (France)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f University of Zagreb   (Croatia)

^g ROYAL VICTORIA INFIRMARY   (United Kingdom)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE; TYROSINE;

ANTIBODY LABELING; ARTICLE; B CELL LYMPHOMA; CARCINOGENESIS; CELL MEMBRANE; CELL NUCLEUS; CHRONIC LYMPHATIC LEUKEMIA; CYTOPLASM; ENZYME ACTIVATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMATOID PAPULOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T CELL LYMPHOMA; TUMOR CELL;

CELL NUCLEUS; CYTOPLASM; HUMANS; LYMPHOMA, NON-HODGKIN; LYMPHOMATOID PAPULOSIS; MICROFILAMENT PROTEINS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN-TYROSINE KINASES; TYROSINE;

EID: 10744231498     PISSN: 00182214     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026032902888     Document Type: Article

References (59)

1. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J (1998) Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18: 6951-6961.
2. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G (1998) ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 91: 2076-2084.
3. Bischof D, Pulford K, Mason DY, Morris SW (1997) Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17: 2312-2325.
4. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411: 355-365.
5. Colleoni GWB, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M (2000) ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from recurrent cryptic chromosomal inversion, inv(2)(p23q35). Amer J Pathol 156: 781-789.
6. Copie-Bergman C, Boulland ML, Dehoulle C, Moller P, Farcet JP, Dyer MJ, Haioun C, Romeo PH, Gaulard P, Leroy K (2003) Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood 101: 2756-2761.
7. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY (1984) Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219-229.
8. Cordell JL, Pulford KA, Bigerna B, Roncador G, Banham A, Colombo E, Pelicci PG, Mason DY, Falini B (1999) Detection of normal and chimeric nucleophosmin in human cells. Blood 93: 632-642.
9. Defrance T, Fluckiger AC, Rossi JF, Magaud JP, Sotto JJ, Banchereau J (1992) Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin's malignant B-lymphoma cells. Blood 79: 990-996.
10. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, Al Saati T, Cerretti DP, Morris SW, Mason DY (1997) A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 89: 1483-1490.
11. Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20: 5623-5637.
12. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, Pelicci PG, Flenghi L (1998) ALK expression defines a distinct group of T/null lymphomas ('ALK lymphomas') with a wide morphological spectrum. Am J Pathol 153: 875-886.
13. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonal V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss H-D, Araujo I, Fizzotti M, Pelicci P-G, Flenghi L, Martelli MF, Santucci A (1999) ALK+ lymphoma: Clinico-pathological findings and outcome. Blood 93: 2697-2706.
14. Fantl WJ, Johnson DE, Williams LT (1993) Signalling by receptor tyrosine kinases. Annu Rev Biochem 62: 453-481.
15. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Griner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93: 3913-3921.
16. Gee K, Kozlowski M, Kryworuchko M, Diaz-Mitoma F, Kumar A (2001) Differential effect of 1L-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: Loss of IL-13 receptors on Burkitt's lymphoma B cells. Cell Immunol 211: 131-142.
17. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG (1996) Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukaemia. Mol Cell Biol 16: 4107-4116.
18. Gotoh A, Broxmeyer HE (1997) The function of BCR/ABL and related proto-oncogenes. Curr Opin Hematol 4: 3-11.
19. XL chimeric gene with transforming activity. Am J Pathol 160: 1487-1494.
20. Hernandez L, Pinyol M, Hernandez S, Bea S, Pulford K, Rosenwald A, Lamant L, Falini B, Ott G, Mason DY, Delsol G, Campo E (1999) TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94: 3265-3268.
21. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. (2001) In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press.
22. Jones EA, Pringle JH, Angel CA, Rees RC (2002) Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL). Leuk Lymphoma 43: 1313-1321.
23. Joos S, Kupper M, Ohl S, von Bonin F, Mechtersheimer G, Bentz M, Marynen P, Moller P, Pfreundschuh M, Trumper L, Lichter P (2000) Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60: 549-552.
24. Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, Martin-Subero JI, Wolf J, Adamowicz M, Barth TF, Lichter P, Jauch A (2003) Hodgkin's lymphoma cell lines are characterised by frequent aberrations on chromosomes 2p and 9q including REL and JAK2. Int J Cancer 103: 489-495.
25. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME (1993) A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 17: 859-868.
26. Kolibaba KS, Druker BJ (1997) Protein tyrosine kinases and cancer. Biochimica Biophys Acta 1333: F217-F248.
27. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V, Tesch H (2001) STAT3 is constitutively activated in Hodgkin cell lines. Blood 98: 762-770.
28. Kuefer M, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY, Morris SW (1997) Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90: 2901-2910.
29. Kurzrock R, Gutterman J, Talpaz M (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319: 990-998.
30. Labouyrie M, Parrens M, de Mascarel A, Bloch B, Merlio J-P (1997) Distribution of NGF receptors in normal and pathologic human lymphoid tissues. J Neuroimmunol 77: 161-173.
31. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278: 1309-1312.
32. Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B (1999) A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93: 3088-3095.
33. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R (2003) HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 101: 433-440.
34. Lynch SA, Brugge JS, Fromowitz F, Glantz L, Wang P, Caruso R, Viola MV (1993) Increased expression of the src proto-oncogene in hairy cell leukemia and a subgroup of B-cell lymphomas. Leukemia 7: 1416-1422.
35. Ma Z, Cools J, Marynan P, Cui X, Siebert R, Gesk S, Schlegelberger B, Peeters B, De Wolf-Peeters C, Wlodarska I, Morris SW (2000) Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 95: 2144-2149.
36. Mason DY, Pulford KAF, Bischof D, Kuefer MU, Butler LH, Lamant L, Delsol G, Morris SW (1998) Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res 58: 1057-1062.
37. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284.
38. Morris SW, Xue L, Ma Z, Kinney MC (2001) Alk+ CD30+ lymphomas: A distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol 113: 275-295.
39. Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW and Skorski T (2001) Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 61: 6517-6523.
40. Pawson T (1995) Protein modules and signalling networks. Nature 373: 573-580.
41. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90: 2535-2540.
42. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, Pelicci PG (1992) A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70: 93-104.
43. Pulford K, Delsol G, Roncador G, Biddolph S, Jones M, Mason DY (1999) Immunohistochemical screening for oncogenic tyrosine kinase activation. J Pathol 187: 588-593.
44. Scheijen B, Griffin JD (2002) Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 21: 3314-3333.
45. Schuringa J-J, Wierenga AT, Kruijer W, Vellenga E (2000) Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95: 3765-3770.
46. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S (1994) Hyperphosphorylation of a novel 80 kDa protein tyrosine-kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9: 1567-1574.
47. Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315: 550-554.
48. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T (2001) Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61: 2194-2199.
49. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B (2000) CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 96: 3681-3695.
50. Takemoto S, Mulloy JC, Cereseto A, Migone T-S, Patel BKR, Matsuoka M, Yamaguchi K, Takatsuki K, Kamihara S, White JD, Leonard WJ, Waldmann TG, Franchini G (1997) Proliferation of adult T cell leukaemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA 94: 13897-13902.
51. Tort F, Pinyol M, Pulford K, Roncador G, Hernandez L, Nayach I, Kluin-Nelemans HC, Kluin P, Touriol C, Delsol G, Mason D, Campo E (2001) Molecular characterisation of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphomas. Lab Invest 81: 419-426.
52. Touriol C, Greenland C, Lamant L, Pulford K, Bernard F, Rousset T, Mason DY, Delsol G (2000) Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95: 3204-3207.
53. Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, Pelicci P-G, Falini B (2000) A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 60: 793-798.
54. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212.
55. von Knethen A, Abts H, Kube D, Diehl V, Tesch H (1997) Expression of p561ck in B-cell neoplasias. Leuk Lymphoma 26: 551-562.
56. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 56: 5499-5505.
57. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G (2002) Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21: 1038-1047.
58. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, Shaw LM, Wasik MA (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 93: 9148-9153.
59. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA (2002) Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168: 466-474.